

Anthera Pharmaceuticals Inc  
 Form 4  
 April 14, 2011

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 TRUEX PAUL F

(Last) (First) (Middle)

C/O ANTHERA  
 PHARMACEUTICALS,  
 INC., 25801 INDUSTRIAL  
 BOULEVARD, SUITE B

(Street)

HAYWARD, CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
 Anthera Pharmaceuticals Inc  
 [ANTH]

3. Date of Earliest Transaction  
 (Month/Day/Year)  
 04/13/2011

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
 President and CEO

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/30/2011		G <sup>(1)</sup>	V 693,253 D \$ 0	91,122	D	
Common Stock	03/30/2011		G <sup>(1)</sup>	V 693,253 A \$ 0	693,253	I	By trust
Common Stock	04/07/2011		G <sup>(2)</sup>	V 7,250 D \$ 0	686,003	I	By trust
Common Stock	04/13/2011		M	30,000 A \$ 0.26	121,122	D	

Edgar Filing: Anthera Pharmaceuticals Inc - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option (right to buy)	\$ 0.26	04/13/2011		M	30,000	<sup>(3)</sup> 01/23/2017	Common Stock	30,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
TRUEX PAUL F C/O ANTHERA PHARMACEUTICALS, INC. 25801 INDUSTRIAL BOULEVARD, SUITE B HAYWARD, CA 94545	X		President and CEO	

## Signatures

Bradley A. Bugdanowitz, by power of attorney  
Date: 04/14/2011

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The Reporting Person transferred 693,253 shares to The 2005 Truex Family Trust u/d/t April 20, 2005 on March 30, 2011.

(2) This transaction involved a gift of securities by the Reporting Person to his children's trust, The 2006 Truex Irrevocable Trust, u/d/t April 6, 2006 (the "2006 Trust"), who shares Reporting Person's household. The Reporting Person disclaims beneficial ownership of the shares held by the 2006 Trust, and this report should not be deemed an admission that the Reporting Person is the beneficial owner of the 2006 Trust's shares for purposes of Section 16 or for any other purpose.

(3)

## Edgar Filing: Anthera Pharmaceuticals Inc - Form 4

100% of the shares subject to this Stock Option were immediately exercisable. However, all unvested shares underlying this Stock Option were subject to a right of repurchase held by the Issuer, which lapsed according to the following vesting schedule: 25% of the total number of shares vest on the first anniversary of October 3, 2005 vesting start date (the "Vesting Start Date") and pro-rata monthly thereafter. This Stock Option has completely vested on the fourth anniversary of the Vesting Start Date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.